Published on by CAD Awards

Dr. Nagendra Verma | Life Sciences | Best Researcher Award 

Research specialist| St. Cloud State University | United States

Dr. Nagendra Verma is a highly accomplished biomedical scientist specializing in cellular and molecular biology, molecular oncology, and regenerative medicine, with over a decade of international research experience. His work focuses on the therapeutic and regulatory roles of extracellular vesicles (EVs) and microRNAs in ocular and cancer biology, particularly exploring their applications in corneal wound healing, stem cell regulation, and STAT3-dependent cancer inhibition. Dr. Verma has authored 11 research publications, cited 104 times by 95 documents, achieving an h-index of 7. His research demonstrates a strong command of molecular diagnostics, genomics, and biophysical methodologies, contributing to significant advancements in understanding disease mechanisms and developing novel therapeutic interventions. He has collaborated extensively within interdisciplinary academic and industrial environments, reflecting his ability to integrate scientific innovation with translational potential. As an active member of global scientific societies such as ARVO, RAPS, and AAMI, Dr. Verma also serves as a reviewer and editorial board member for numerous international journals, including Scientific Reports, Cells, and Molecular Vision. His contributions extend beyond research through mentoring students, presenting at international conferences, and earning recognition for excellence in scientific investigation. Dr. Verma’s work continues to bridge molecular insights with therapeutic innovation, emphasizing precision, collaboration, and impactful discovery in biomedical science.

Profiles: Scopus | Orcid

Featured Publications

  • Verma, N., Franchitto, M., Zonfrilli, A., Cialfi, S., Palermo, R., & Talora, C. (2019). DNA damage stress: Cui prodest? International Journal of Molecular Sciences, 20(5), 1073.

  • Verma, N., Khare, D., Poe, A. J., Amador, C., Ghiam, S., Fealy, A., Ebrahimi, S., Shadrokh, O., Song, X.-Y., Santiskulvong, C., et al. (2023). MicroRNA and protein cargos of human limbal epithelial cell-derived exosomes and their regulatory roles in limbal stromal cells of diabetic and non-diabetic corneas. Cells, 12.

  • Verma, N., Arora, S., Singh, A. K., & Kumar, A. (2025). Extracellular vesicle-associated miRNAs in cornea health and disease: Diagnostic potential and therapeutic implications. Targets, 3(32).

  • Verma, N., Arora, S., Singh, A. K., & Ahmed, J. (2025). Unlocking the potential of exosomes (extracellular vesicles): Drug delivery advancements and therapeutics in ocular diseases. RSC Pharmaceutics, 1(97).

  • Verma, N., & Arora, S. (2025). Navigating the global regulatory landscape for exosome-based therapeutics: Challenges, strategies, and future directions. Pharmaceutics, 17(990).

  • Arora, S., & Verma, N. (2024). Advancing organic electronics through the lens of ionic liquids and polymerized ionic liquids: A review. RSC Applied Polymers.

  • Arora, S., & Verma, N. (2024). Exosomal microRNAs as potential biomarkers and therapeutic targets in corneal diseases. Molecular Vision, 30, 92–106.

  • De Blasio, C., Verma, N., Moretti, M., Cialfi, S., Zonfrilli, A., Franchitto, M., Truglio, F., De Smaele, E., Ichijo, H., Naguro, I., Screpanti, I., & Talora, C. (2021). Functional cooperation between ASK1 and p21(Waf1/Cip1) in the balance of cell-cycle arrest, cell death, and tumorigenesis of stressed keratinocytes. Cell Death Discovery, 7(1), 75.

  • De Blasio, C., Zonfrilli, A., Franchitto, M., Mariano, G., Cialfi, S., Verma, N., Checquolo, S., Bellavia, D., Palermo, R., Benelli, D., Screpanti, I., & Talora, C. (2019). PLK1 targets NOTCH1 during DNA damage and mitotic progression. Journal of Biological Chemistry, 294(47), 17941–17950.

  • Yue, P., Zhu, Y., Brotherton-Pleiss, C., Fu, W., Verma, N., Chen, J., Nakamura, K., Chen, W., Chen, Y., Alonso-Valenteen, F., Mikhael, S., Medina-Kauwe, L., Kershaw, K. M., Celeridad, M., Pan, S., Limpert, A. S., Sheffler, D. J., Cosford, N. D. P., Shiao, S. L., & Turkson, J. (2022). Novel potent azetidine-based compounds irreversibly inhibit STAT3 activation and induce antitumor response against human breast tumor growth in vivo. Cancer Letters, 534, 215613.

 

 

 

Nagendra Verma | Life Sciences | Best Researcher Award

You May Also Like